Chinese General Practice ›› 2021, Vol. 24 ›› Issue (33): 4177-4184.DOI: 10.12114/j.issn.1007-9572.2021.02.001
Special Issue: 肿瘤最新文章合辑
• Monographic Research • Previous Articles Next Articles
Published:
2021-11-20
Online:
2021-11-20
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.001
[1]SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.DOI:10.3322/caac.21660. [2]SIEGEL R L,TORRE L A,SOERJOMATARAM I,et al.Global patterns and trends in colorectal cancer incidence in young adults[J].Gut,2019,68(12):2179-2185.DOI:10.1136/gutjnl-2019-319511. [3]LUI R N,TSOI K K F,HO J M W,et al.Global increasing incidence of young-onset colorectal cancer across 5 continents:a joinpoint regression analysis of 1,922,167 cases[J].Cancer Epidemiol Biomarkers Prev,2019,28(8):1275-1282.DOI:10.1158/1055-9965.EPI-18-1111. [4]LOOMANS-KROPP H A,UMAR A.Increasing incidence of colorectal cancer in young adults[J].J Cancer Epidemiol,2019,2019:1-9.DOI:10.1155/2019/9841295. [5]VUIK F E,NIEUWENBURG S A,BARDOU M,et al.Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years[J].Gut,2019,68(10):1820-1826.DOI:10.1136/gutjnl-2018-317592. [6]吴春晓,顾凯,龚杨明,等.2015年中国结直肠癌发病和死亡情况分析[J].中国癌症杂志,2020,30(4):241-245.DOI:10.19401/j.cnki.1007-3639.2020.04.001. WU C X,GU K,GONG Y M,et al.Analysis of incidence and mortality of colorectal cancer in China,2015[J].China Oncol,2020,30(4):241-245.DOI:10.19401/j.cnki.1007-3639.2020.04.001. [7]ZHANG L,CAO F,ZHANG G Y,et al.Trends in and predictions of colorectal cancer incidence and mortality in China from 1990 to 2025[J].Front Oncol,2019,9:98.DOI:10.3389/fonc.2019.00098. [8]GENEVE N,KAIRYS D,BEAN B,et al.Colorectal cancer screening[J].Prim Care,2019,46(1):135-148.DOI:10.1016/j.pop.2018.11.001. [9]KAHI C J.Reviewing the evidence that polypectomy prevents cancer[J].Gastrointest Endosc Clin N Am,2019,29(4):577-585.DOI:10.1016/j.giec.2019.05.001. [10]SHARMA T.Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults[J].Public Health,2020,182:70-76.DOI:10.1016/j.puhe.2020.01.021. [11]PROVENZALE D,NESS R M,LLOR X,et al.NCCN guidelines insights:colorectal cancer screening,version 2.2020[J].J Natl Compr Canc Netw,2020,18(10):1312-1320.DOI:10.6004/jnccn.2020.0048. [12]李鹏,王拥军,陈光勇,等.中国早期结直肠癌及癌前病变筛查与诊治共识[J].中国实用内科杂志,2015,35(3):211-227. DOI:10.7504/nk2015020301. [13]YANG Y,WANG H Y,CHEN Y K,et al.Current status of surgical treatment of rectal cancer in China[J].Chin Med J (Engl),2020,133(22):2703-2711.DOI:10.1097/CM9.0000000000001076. [14]WOLF A M D,FONTHAM E T H,CHURCH T R,et al.Colorectal cancer screening for average-risk adults:2018 guideline update from the American Cancer Society[J].CA Cancer J Clin,2018,68(4):250-281.DOI:10.3322/caac.21457. [15]LEDDIN D,LIEBERMAN D A,TSE F,et al.Clinical practice guideline on screening for colorectal cancer in individuals with a family history of nonhereditary colorectal cancer or adenoma:the Canadian association of gastroenterology Banff consensus[J].Gastroenterology,2018,155(5):1325-1347.e3.DOI:10.1053/j.gastro.2018.08.017. [16]BAGLIONI P.The IARC perspective on colorectal cancer screening[J].N Engl J Med,2018,379(3):301.DOI:10.1056/NEJMc1807173. [17]BARICHELLO S,DENG L,ISMOND K P,et al.Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies[J].Int J Colorectal Dis,2019,34(11):1953-1962.DOI:10.1007/s00384-019-03419-7. [18]RAN T,CHENG C Y,MISSELWITZ B,et al.Cost-effectiveness of colorectal cancer screening strategies——a systematic review[J].Clin Gastroenterol Hepatol,2019,17(10):1969-1981.e15.DOI:10.1016/j.cgh.2019.01.014. [19]CALDERWOOD A H.Importance of age-specific insurer perspective on lifetime cost effectiveness of colorectal cancer screening[J].Am J Gastroenterol,2018,113(12):1754-1756.DOI:10.1038/s41395-018-0386-z. [20]LEW J B,ST JOHN D J B,MACRAE F A,et al.Evaluation of the benefits,harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia[J].Int J Cancer,2018,143(2):269-282.DOI:10.1002/ijc.31314. [21]JAHN B,SROCZYNSKI G,BUNDO M,et al.Effectiveness,benefit harm and cost effectiveness of colorectal cancer screening in Austria[J].BMC Gastroenterol,2019,19(1):209.DOI:10.1186/s12876-019-1121-y. [22]TANDAY S.Updated Canadian colorectal cancer screening guidelines[J].Lancet Oncol,2016,17(4):e137.DOI:10.1016/S1470-2045(16)00139-X. [23]REX D K,BOLAND C R,DOMINITZ J A,et al.Colorectal cancer screening:recommendations for physicians and patients from the US multi-society task force on colorectal cancer[J].Gastroenterology,2017,153(1):307-323.DOI:10.1053/j.gastro.2017.05.013. [24]HADJILIADIS D,KHORUTS A,ZAUBER A G,et al.Cystic fibrosis colorectal cancer screening consensus recommendations[J].Gastroenterology,2018,154(3):736-745.e14.DOI:10.1053/j.gastro.2017.12.012. [25]YEE J,KIM D H,ROSEN M P,et al.ACR Appropriateness Criteria colorectal cancer screening[J].J Am Coll Radiol,2014,11(6):543-551.DOI:10.1016/j.jacr.2014.02.006. [26]LOPES G,STERN M C,TEMIN S,et al.Early detection for colorectal cancer:ASCO resource-stratified guideline[J].J Glob Oncol,2019,5:1-22.DOI:10.1200/JGO.18.00213. [27]MONAHAN K J,BRADSHAW N,DOLWANI S,et al.Guidelines for the management of hereditary colorectal cancer from the British society of gastroenterology (BSG)/association of coloproctology of great Britain and Ireland (ACPGBI)/united kingdom cancer genetics group (UKCGG)[J].Gut,2020,69(3):411-444.DOI:10.1136/gutjnl-2019-319915. [28]US Preventive Services Task Force,BIBBINS-DOMINGO K,GROSSMAN D C,et al.Screening for colorectal cancer:US preventive services task force recommendation statement[J].JAMA,2016,315(23):2564-2575.DOI:10.1001/jama.2016.5989. [29]The Lancet Gastroenterology Hepatology.USPSTF recommends expansion of colorectal cancer screening[J].Lancet Gastroenterol Hepatol,2021,6(1):1.DOI:10.1016/S2468-1253(20)30361-7. [30]SILVA-ILLANES N,ESPINOZA M.Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening:a systematic review[J].Value Health,2018,21(7):858-873.DOI:10.1016/j.jval.2017.11.010. [31]柏愚,杨帆,马丹,等.中国早期结直肠癌筛查及内镜诊治指南(2014年,北京)[J].胃肠病学,2015,20(6):345-365. DOI:10.3969/j.issn.1008-7125.2015.06.006. [32]郑树,张苏展,蔡三军,等.中国结直肠肿瘤早诊筛查策略专家共识[J].中华胃肠外科杂志,2018,21(10):1081-1086.DOI:10.3760/cma.j.issn.1671-0274.2018.10.001. ZHENG S,ZHANG S Z,CAI S J,et al.Expert consensus on early diagnosis and screening strategies for colorectal tumors in China [J].Chinese Journal of Gastrointestinal Surgery,2018,21(10):1081-1086.DOI:10.3760/cma.j.issn.1671-0274.2018.10.001. [33]国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化内镜学分会,等.中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J].中华医学杂志,2019,99(38):2961-2970.DOI:10.3760/cma.j.issn.0376-2491.2019.38.001. [34]国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组.中国结直肠癌筛查与早诊早治指南(2020,北京)[J].中华肿瘤杂志,2021,43(1):16-38.DOI:10.3760/cma.j.cn112152-20210105-00010. National Cancer Center,China,Expert Group of the Development of China Guideline for the Screening,Early Detection and Early Treatment of Colorectal Cancer.China guideline for the screening,early detection and early treatment of colorectal cancer(2020,Beijing)[J].Chin J Oncol,2021,43(1):16-38.DOI:10.3760/cma.j.cn112152-20210105-00010. [35]CENIN D R,NABER S K,DE WEERDT A C,et al.Cost-effectiveness of personalized screening for colorectal cancer based on polygenic risk and family history[J].Cancer Epidemiol Biomarkers Prev,2020,29(1):10-21.DOI:10.1158/1055-9965.EPI-18-1123. [36]SUBRAMANIAN S,BOBASHEV G,MORRIS R J,et al.Personalized medicine for prevention:can risk stratified screening decrease colorectal cancer mortality at an acceptable cost?[J].Cancer Causes Control,2017,28(4):299-308.DOI:10.1007/s10552-017-0864-4. [37]NABER S K,KUNDU,KUNTZ K M,et al.Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk:current status and future potential[J].JNCI Cancer Spectr,2020,4(1):pkz086.DOI:10.1093/jncics/pkz086. [38]KNUDSEN A B,ZAUBER A G,RUTTER C M,et al.Estimation of benefits,burden,and harms of colorectal cancer screening strategies:modeling study for the US preventive services task force[J].JAMA,2016,315(23):2595-2609.DOI:10.1001/jama.2016.6828. [39]LADABAUM U,MANNALITHARA A,MEESTER R G S,et al.Cost-effectiveness and national effects of initiating colorectal cancer screening for average-risk persons at age 45 years instead of 50 years[J].Gastroenterology,2019,157(1):137-148.DOI:10.1053/j.gastro.2019.03.023. [40]ROBERTSON D J,LADABAUM U.Opportunities and challenges in moving from current guidelines to personalized colorectal cancer screening[J].Gastroenterology,2019,156(4):904-917.DOI:10.1053/j.gastro.2018.12.012. [41]LIEBERMAN D.Race,gender,and colorectal cancer screening[J].Am J Gastroenterol,2005,100(12):2756-2758.DOI:10.1111/j.1572-0241.2005.00352.x. [42]MEESTER R G S,PETERSE E F P,KNUDSEN A B,et al.Optimizing colorectal cancer screening by race and sex:Microsimulation analysis Ⅱ to inform the American Cancer Society colorectal cancer screening guideline[J].Cancer,2018,124(14):2974-2985.DOI:10.1002/cncr.31542. [43]OHRI A,ROBINSON A,LIU B,et al.Updated assessment of colorectal cancer incidence in the U.S.by age,sex,and race/ethnicity[J].Dig Dis Sci,2020,65(6):1838-1849.DOI:10.1007/s10620-019-05913-y. [44]SCHOENFELD P.Quality in colorectal cancer screening with colonoscopy[J].Gastrointest Endosc Clin N Am,2020,30(3):541-551.DOI:10.1016/j.giec.2020.02.014. [45]NABER S K,KUNTZ K M,HENRIKSON N B,et al.Cost effectiveness of age-specific screening intervals for people with family histories of colorectal cancer[J].Gastroenterology,2018,154(1):105-116.e20.DOI:10.1053/j.gastro.2017.09.021. [46]KAMINSKI M F,ROBERTSON D J,SENORE C,et al.Optimizing the quality of colorectal cancer screening worldwide[J].Gastroenterology,2020,158(2):404-417.DOI:10.1053/j.gastro.2019.11.026. [47]DE KLERK C M,GUPTA S,DEKKER E,et al.Socioeconomic and ethnic inequities within organised colorectal cancer screening programmes worldwide[J].Gut,2018,67(4):679-687.DOI:10.1136/gutjnl-2016-313311. [48]CHEN H D,LI N,REN J S,et al.Participation and yield of a population-based colorectal cancer screening programme in China[J].Gut,2019,68(8):1450-1457.DOI:10.1136/gutjnl-2018-317124. [49]朱慧蓉,刘天威.上海市某社区全科门诊接诊患者结直肠癌筛查认知现状的调查[J].中国全科医学,2017,20(S2):270-273. ZHU H R,LIU T W.A survey on knowledge of screening for colorectal cancer among outpatients in community of Shanghai[J].Chinese General Practice,2017,20(S2):270-273. [50]PILONIS N D,BUGAJSKI M,WIESZCZY P,et al.Participation in competing strategies for colorectal cancer screening:a randomized health services study (PICCOLINO study)[J].Gastroenterology,2021,160(4):1097-1105.DOI:10.1053/j.gastro.2020.11.049. [51]安锦慧,孙治平,李云涛,等.我国结直肠癌筛查的影响因素文献分析及思考[J].中国全科医学,2020,23(23):2877-2882.DOI:10.12114/j.issn.1007-9572.2020.00.160. AN J H,SUN Z P,LI Y T,et al.Literature review and consideration of factors influencing colorectal cancer screening in China[J].Chinese General Practice,2020,23(23):2877-2882.DOI:10.12114/j.issn.1007-9572.2020.00.160. [52]DE BEKKER-GROB E W,DONKERS B,VELDWIJK J,et al.What factors influence non-participation most in colorectal cancer screening? A discrete choice experiment[J].Patient,2021,14(2):269-281.DOI:10.1007/s40271-020-00477-w. [53]ZHANG J G,XU H F,ZHENG L Y,et al.Determinants of participation and detection rate of colorectal cancer from a population-based screening program in China[J].Front Oncol,2020,10:1173.DOI:10.3389/fonc.2020.01173. [54]DHARNI N,ARMSTRONG D,CHUNG-FAYE G,et al.Factors influencing participation in colorectal cancer screening——a qualitative study in an ethnic and socio-economically diverse inner city population[J].Health Expect,2017,20(4):608-617.DOI:10.1111/hex.12489. [55]MEESTER R G,DOUBENI C A,ZAUBER A G,et al.Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018[J].Cancer,2015,121(13):2281-2285.DOI:10.1002/cncr.29336. [56]HEAVENER T,MCSTAY F W,JAEGER V,et al.Assessing adherence and cost-benefit of colorectal cancer screening for accountable providers[J].Proc (Bayl Univ Med Cent),2019,32(4):490-497.DOI:10.1080/08998280.2019.1647702. |
[1] | XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852. |
[2] | HU Jieman, TAN Feixiang, YUAN Anxin, CHEN Shiyu, TANG Chulei, YIN Yueheng, BA Lei, XU Qin. Analysis of the Trajectory of Postoperative Frailty and Influencing Factors in Patients with Colorectal Cancer [J]. Chinese General Practice, 2025, 28(26): 3276-3282. |
[3] | YU Wenhua, LI Jianguo, DUAN Wenyan, GAO Xuyan, LI Xiaxia, ZHANG Zilong, ZHANG Li, MA Lina. Reliability and Validity of the Function Impairment Screening Tool among Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(24): 3000-3004. |
[4] | SHI Jiarui, WANG Zili, ZHANG Xueqing, SONG Yulei, XU Guihua, BAI Yamei. The Current Status of Initial Cognitive Screening Services in Community-based Cognitive Services Centers in Nanjing [J]. Chinese General Practice, 2025, 28(22): 2784-2790. |
[5] | LI Jia, TAN Wenbin. The Dilemma of Prevention and Treatment of Secondary Osteoporosis and Its Countermeasures [J]. Chinese General Practice, 2025, 28(17): 2075-2081. |
[6] | ZHANG Qi, HE Shen, LI Hua. Interpretation of Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement 2022 [J]. Chinese General Practice, 2025, 28(15): 1823-1830. |
[7] | ZENG Yongtian, CHEN Riling, NONG Xueyan, LIU Zhou, LIANG Lizhong, ZHU Zijian. Clinical Research Progress and Challenges of Digital Therapeutics from Screening to Intervention in Autism Spectrum Disorder [J]. Chinese General Practice, 2025, 28(14): 1702-1708. |
[8] | WU Dadong, LIU Huimin, ZHANG Jiayi, LIU Siyuan, ZHAO Guanglin, JIN Shuyan, JIANG Lei. Application and Evaluation of the Mobile Platform for Perinatal Depression Screening and Intervention [J]. Chinese General Practice, 2025, 28(14): 1773-1780. |
[9] | CHI Xun, LIU Sisi, CHEN Qiao, HU Yue, WANG Weixian. The Suitability of Four Nutritional Screening Tools for Nutritional Screening in Patients with Cirrhosis: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(11): 1395-1402. |
[10] | SHU Ting, LAN Zhipeng, WU Xia, LUO Yingjuan, YANG Liu. Study on the Infection and Related Factors of High-risk HPV in Cervical Cancer Screening Women: Based on 450 000 Participants in Chengdu [J]. Chinese General Practice, 2025, 28(02): 213-219. |
[11] | ZHANG Shuo, ZHANG Long, ZHANG Yan, LI Jianping. Advances in Molecular Biotechnology for Diagnosing and Treating Familial Hypercholesterolemia [J]. Chinese General Practice, 2024, 27(36): 4498-4504. |
[12] | LI Yuan, MA Hongyang, LI Biao, YUE Anna, SHAO Yaqing, SUN Kangyun. Clinical Significance of Screening for Familial Hypercholesterolemia in Patients with Hypercholesterolemia [J]. Chinese General Practice, 2024, 27(36): 4515-4521. |
[13] | LUO Qin, GOU Lianping, CHEN Yin, SU Feng. Comparison of the Diagnostic Value of Calf Circumference, Upper Arm Circumference and Ishii Score in Patients with Coronary Heart Disease Complicated with Sarcopenia [J]. Chinese General Practice, 2024, 27(35): 4403-4411. |
[14] | ZHU Suyan, ZHENG Xiaomeng, FAN Miao, CHEN Chunyan. Interpretation of the Screening Tool of Older Person's Potentially Inappropriate Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) Criteria (Version 3) [J]. Chinese General Practice, 2024, 27(33): 4097-4104. |
[15] | ZHOU Zhensen, HUANG Yan, CHENG Siwei, ZHANG Xiaoyu, ZHANG Xiaoyu, SUN Ting, YANG Xianjun, XIE Hui, MA Zuchang. Construction and Validation of a Screening Model for Early Atherosclerosis Risk in the Aorta [J]. Chinese General Practice, 2024, 27(33): 4147-4154. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||